<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30288124</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1179-1349</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Clinical epidemiology</Title>                <ISOAbbreviation>Clin Epidemiol</ISOAbbreviation>            </Journal>            <ArticleTitle>Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.</ArticleTitle>            <Pagination>                <MedlinePgn>1349-1358</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CLEP.S175063</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US.</AbstractText>                <AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Electronic health records from oncology clinics were used to identify women diagnosed with bone metastasis from breast cancer between 2013 and 2014. Patients were excluded if they had recently used a BMA or had concurrent cancer at an additional primary site. The incidence of BMA initiation, interruption, and reinitiation were estimated using competing risk regression models. A generalized linear model was used to estimate risk factors for treatment initiation and interruption.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">There were 589 women diagnosed with bone metastasis from breast cancer. By 1 year, 68% of these patients (95% CI: 64%, 71%) had initiated treatment with a BMA. Denosumab and zoledronic acid were the most commonly used agents, whereas pamidronate was used infrequently. Young women were more likely to initiate a BMA than older women (adjusted risk difference: 6.4 [95% CI: 1.5, 10.9]). Of the 412 patients who initiated a BMA, 46% (95% CI: 41%, 51%) experienced an interruption within 1 year. Seventy-four percent (95% CI: 68%, 79%) of patients who interrupted their treatment had reinitiated therapy within 1 year of interruption.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>McGrath</LastName>                    <ForeName>Leah J</ForeName>                    <Initials>LJ</Initials>                    <AffiliationInfo>                        <Affiliation>NoviSci, LLC, Durham, NC, USA, lmcgrath@novisci.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Overman</LastName>                    <ForeName>Robert A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>NoviSci, LLC, Durham, NC, USA, lmcgrath@novisci.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reams</LastName>                    <ForeName>Diane</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>NoviSci, LLC, Durham, NC, USA, lmcgrath@novisci.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cetin</LastName>                    <ForeName>Karynsa</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Amgen Inc, Thousand Oaks, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liede</LastName>                    <ForeName>Alexander</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Amgen Inc, South San Franscisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Narod</LastName>                    <ForeName>Steven A</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brookhart</LastName>                    <ForeName>M Alan</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>NoviSci, LLC, Durham, NC, USA, lmcgrath@novisci.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hernandez</LastName>                    <ForeName>Rohini K</ForeName>                    <Initials>RK</Initials>                    <AffiliationInfo>                        <Affiliation>Amgen Inc, Thousand Oaks, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Clin Epidemiol</MedlineTA>            <NlmUniqueID>101531700</NlmUniqueID>            <ISSNLinking>1179-1349</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1-50; quiz S51</RefSource>                <PMID Version="1">23997241</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2011 Jan 24;11:29</RefSource>                <PMID Version="1">21261987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2018 Apr;26(4):1029-1038</RefSource>                <PMID Version="1">29387997</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Dec 10;35(35):3978-3986</RefSource>                <PMID Version="1">29035643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2006 Mar;3(3):e25</RefSource>                <PMID Version="1">16409108</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2011 Jun;11(3):177-83</RefSource>                <PMID Version="1">21665138</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Bone Oncol. 2018 Feb 03;11:38-50</RefSource>                <PMID Version="1">29511626</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2016 Apr;156(3):587-595</RefSource>                <PMID Version="1">27083181</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2018 Jan;68(1):7-30</RefSource>                <PMID Version="1">29313949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 1998 May 21;338(21):1516-20</RefSource>                <PMID Version="1">9593791</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Econ. 2014 Mar;17(3):223-30</RefSource>                <PMID Version="1">24494707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 Sep 20;24(27):4377-83</RefSource>                <PMID Version="1">16983106</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2017 Jul;79:139-148</RefSource>                <PMID Version="1">28494404</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2013 Jan;49(2):416-30</RefSource>                <PMID Version="1">22906748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2018 Jan 6;18(1):44</RefSource>                <PMID Version="1">29306325</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Aug 1;32(22):2318-27</RefSource>                <PMID Version="1">24934786</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2011 Mar 20;29(9):1221-7</RefSource>                <PMID Version="1">21343561</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56</RefSource>                <PMID Version="1">25234529</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2009 May 5;150(9):604-12</RefSource>                <PMID Version="1">19414839</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Epidemiol. 2012;4:87-93</RefSource>                <PMID Version="1">22570568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2017 Jan 3;317(1):48-58</RefSource>                <PMID Version="1">28030702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Bone Miner Res. 2015 Jan;30(1):3-23</RefSource>                <PMID Version="1">25414052</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epidemiology. 2001 Nov;12(6):682-9</RefSource>                <PMID Version="1">11679797</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Epidemiol. 2015 Jul 17;7:335-45</RefSource>                <PMID Version="1">26229504</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2008 Sep 15;113(6):1438-45</RefSource>                <PMID Version="1">18720527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2005 May 23;92(10):1869-76</RefSource>                <PMID Version="1">15870721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s</RefSource>                <PMID Version="1">17062708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Jan;131(1):231-8</RefSource>                <PMID Version="1">21842243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Epidemiol. 2006 Apr;35(2):345-52</RefSource>                <PMID Version="1">16368724</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):229-238</RefSource>                <PMID Version="1">29316026</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Epidemiol. 2015 Nov 11;7:441-8</RefSource>                <PMID Version="1">26635485</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Dec 10;28(35):5132-9</RefSource>                <PMID Version="1">21060033</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 May 10;25(14):1858-69</RefSource>                <PMID Version="1">17488984</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2017 Jun;25(6):1845-1851</RefSource>                <PMID Version="1">28120114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474</RefSource>                <PMID Version="1">22336790</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Jun;14(7):663-70</RefSource>                <PMID Version="1">23684411</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2016 Jan;24(1):447-55</RefSource>                <PMID Version="1">26335402</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 20;353(16):1652-4</RefSource>                <PMID Version="1">16236735</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">bone metastasis</Keyword>            <Keyword MajorTopicYN="N">bone-modifying agents</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">denosumab</Keyword>            <Keyword MajorTopicYN="N">electronic health records</Keyword>            <Keyword MajorTopicYN="N">pamidronate</Keyword>            <Keyword MajorTopicYN="N">treatment patterns</Keyword>            <Keyword MajorTopicYN="N">zoledronic acid</Keyword>        </KeywordList>        <CoiStatement>Disclosure RKH, KC, and AL are employees of Amgen Inc and have stock ownership in Amgen Inc. MAB has had research support from Amgen and AstraZeneca, owns equity in NoviSci, LLC, and has served as a scientific advisor/consultant to Amgen, Merck, TargetPharma, Genentech, AbbVie, and RxAnte, LLC. LJM, RAO, DR, and SAN have no potential conflicts of interest to report in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30288124</ArticleId>            <ArticleId IdType="doi">10.2147/CLEP.S175063</ArticleId>            <ArticleId IdType="pii">clep-10-1349</ArticleId>            <ArticleId IdType="pmc">PMC6162990</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>